- Home
- STTK vs SHMD Comparison
STTK vs SHMD Comparison
Compare STTK & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SHMD
- Stock Information
- Founded
- STTK 2016
- SHMD 1864
- Country
- STTK United States
- SHMD Germany
- Employees
- STTK N/A
- SHMD N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SHMD
- Sector
- STTK Health Care
- SHMD
- Exchange
- STTK Nasdaq
- SHMD Nasdaq
- Market Cap
- STTK 56.8M
- SHMD 144.3M
- IPO Year
- STTK 2020
- SHMD N/A
- Fundamental
- Price
- STTK $1.12
- SHMD $2.58
- Analyst Decision
- STTK Hold
- SHMD
- Analyst Count
- STTK 3
- SHMD 0
- Target Price
- STTK $2.00
- SHMD N/A
- AVG Volume (30 Days)
- STTK 182.2K
- SHMD 51.8K
- Earning Date
- STTK 02-27-2025
- SHMD 02-25-2025
- Dividend Yield
- STTK N/A
- SHMD N/A
- EPS Growth
- STTK N/A
- SHMD 1309.32
- EPS
- STTK N/A
- SHMD 1.07
- Revenue
- STTK $6,435,000.00
- SHMD $99,752,404.00
- Revenue This Year
- STTK $313.04
- SHMD N/A
- Revenue Next Year
- STTK N/A
- SHMD N/A
- P/E Ratio
- STTK N/A
- SHMD $2.30
- Revenue Growth
- STTK 382.75
- SHMD N/A
- 52 Week Low
- STTK $0.94
- SHMD $1.98
- 52 Week High
- STTK $11.76
- SHMD $6.13
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- SHMD N/A
- Support Level
- STTK $1.13
- SHMD N/A
- Resistance Level
- STTK $1.39
- SHMD N/A
- Average True Range (ATR)
- STTK 0.11
- SHMD 0.00
- MACD
- STTK 0.00
- SHMD 0.00
- Stochastic Oscillator
- STTK 18.18
- SHMD 0.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).